Advertisement Eisai acquires MGI Pharma - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Eisai acquires MGI Pharma

Eisai has announced the successful completion of its acquisition of MGI Pharma for approximately $3.9 billion through a cash tender offer followed by a short-form merger of its acquisition vehicle, Jaguar Acquisition Corporation with and into MGI Pharma.

As a result of this acquisition, MGI Pharma becomes a wholly-owned subsidiary of Eisai Corporation of North America.

At the effective time of the merger, all outstanding shares of MGI Pharma common stock not validly tendered and accepted for payment in the tender offer were converted into the right to receive $41 per share in cash (the same price paid in the tender offer), without interest and subject to applicable withholding of taxes.